influenza A (H1N1) 2009 monovalent vaccine

Influenza A (H1N1) 2009 monovalent vaccine is the U.S.-licensed **Novartis** pandemic H1N1 vaccine product indicated for active immunization against disease caused by the 2009 pandemic influenza A H1N1 virus in people aged 4 years and older. It is an egg-derived, inactivated, monovalent influenza vaccine administered as an intramuscular suspension. Vaccination exposes the immune system to H1N1 viral antigen, principally hemagglutinin, to induce protective humoral immune responses against the matched pandemic strain. The FDA lists no trade name for this specific Novartis product and records its initial U.S. approval in 2009. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc5cfd1c-1ff5-4cfa-b544-db8d7f26d46f))

Brand names

PandemrixInfluenza A (H1N1) 2009 Monovalent Vaccine

Other names

h1n1 vaccineh-1n1 vaccineh 1n1 vaccineinfluenza a virus vaccine, h1n1, inactivatedswine flu vaccinepandemic h1n1/09 vaccine